NCT06732960View on ClinicalTrials.gov

A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 21, 2024

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions
Overweight or Obesity
Interventions
BIOLOGICAL

Efsubaglutide Alfa

Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.

OTHER

Placebo

Placebo subcutaneous injection weekly

Trial Locations (3)

200030

Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai

Unknown

Beijing Friendship Hospital, Capital Medical University, Beijing

Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan

All Listed Sponsors
collaborator

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

OTHER

collaborator

Beijing Friendship Hospital

OTHER

collaborator

Jinan Central Hospital

OTHER

lead

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

OTHER

NCT06732960 - A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients | Biotech Hunter | Biotech Hunter